Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility (< 5 μM), toxicity, and side effects issues of this drug. In this context, the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Benizri, Sebastien, Ferey, Ludivine, Alies, Bruno, Mebarek, Naila, Vacher, Gaelle, Appavoo, Ananda, Staedel, Cathy, Gaudin, Karen, Barthélémy, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Nano Express
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764907/
https://www.ncbi.nlm.nih.gov/pubmed/29327307
http://dx.doi.org/10.1186/s11671-017-2420-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764907/
https://www.ncbi.nlm.nih.gov/pubmed/29327307
http://dx.doi.org/10.1186/s11671-017-2420-2

Ejemplares similares